# Generate Biomedicines, Inc. (GENB) > Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/generate-biomedicines-inc/ JSON: https://steadybase.io/company/generate-biomedicines-inc.json Checked Nov 10, 2026. Latest filing read: Aug 6, 2026. ## Company - Legal name: Generate Biomedicines, Inc. - Ticker: GENB (Nasdaq) - SEC CIK: 0002100782 - Industry: Pharmaceutical Preparations (SIC 2834) - Headquarters: Somerville, MA - Fiscal year ends: December 31 - SEC filer category:
Emerging growth company - Website: generatebiomedicines.com - Investor relations: https://investors.generatebiomedicines.com/ - LinkedIn: https://www.linkedin.com/company/generate-biomedicines - Next earnings date: Nov 14, 2026 (estimated from past 8-K timing) ## Key facts - Shares outstanding: 128,352,436 as of Jul 29, 2026 (10-Q filed Aug 6, 2026). Source: https://www.sec.gov/Archives/edgar/data/2100782/000119312526336437/0001193125-26-336437-index.html ## Business We are a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. Our vision is to program biology to generate optimal therapeutics for the greatest impact on human health. Central to our vision is the Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/2100782/000119312526083190/generate_bio_424b4.htm ## Officers and directors - Michael Nally, Chief Executive Officer. LinkedIn: https://www.linkedin.com/in/michael-nally-0a137299. Source: Form 4 filed Mar 6, 2026, https://www.sec.gov/Archives/edgar/data/2100782/000119312526096799/0001193125-26-096799-index.htm - Jason Silvers, President & CFO. LinkedIn: https://linkedin.com/in/jason-silvers-b2975323b. Source: Form 4 filed Mar 2, 2026, https://www.sec.gov/Archives/edgar/data/2100782/000119312526085898/0001193125-26-085898-index.htm - Beth Grous, Chief People Officer. Source: Form 4 filed Mar 2, 2026, https://www.sec.gov/Archives/edgar/data/2100782/000119312526085939/0001193125-26-085939-index.htm - Gevorg Grigoryan, Chief Technology Officer. LinkedIn: https://linkedin.com/in/gevorg-grigoryan-953a8113. Source: Form 4 filed Mar 2, 2026, https://www.sec.gov/Archives/edgar/data/2100782/000119312526085886/0001193125-26-085886-index.htm - Laurie Anne Lee, Chief Medical Officer. Source: Form 4 filed Mar 2, 2026, https://www.sec.gov/Archives/edgar/data/2100782/000119312526085911/0001193125-26-085911-index.htm - Sean Martin, Chief Legal Officer & GC. LinkedIn: https://linkedin.com/in/sean-martin-2926664. Source: Form 4 filed Mar 2, 2026, https://www.sec.gov/Archives/edgar/data/2100782/000119312526085910/0001193125-26-085910-index.htm - Aarif Khakoo, Chief Scientific Officer. LinkedIn: https://linkedin.com/in/aarif-khakoo-a134b64. Source: Form 3 filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/2100782/000119312526078381/0001193125-26-078381-index.htm ## Recent 8-K events - Aug 26, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2100782/000119312526365556/ck0002100782-20260825.htm - Aug 6, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2100782/000119312526336462/ck0002100782-20260806.htm - May 7, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2100782/000119312526209899/ck0002100782-20260507.htm - Mar 2, 2026: Item 5.03, Amendments to articles or bylaws; change in fiscal year; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2100782/000119312526085780/ck0002100782-20260226.htm ## Insider trades (Form 4) - Oct 29, 2026: Frances Arnold (Director) sold 11,409 shares, about $184,733. Source: https://www.sec.gov/Archives/edgar/data/2100782/000119312526447199/0001193125-26-447199-index.htm - Sep 1, 2026: Frances Arnold (Director) sold 1,000 shares, about $16,000. Source: https://www.sec.gov/Archives/edgar/data/2100782/000119312526381875/0001193125-26-381875-index.htm - Mar 4, 2026: Michael Nally (Chief Executive Officer) bought 20,000 shares, about $240,000. Source: https://www.sec.gov/Archives/edgar/data/2100782/000119312526096799/0001193125-26-096799-index.htm - Mar 2, 2026: Beth Grous (Chief People Officer) bought 300 shares, about $4,800. Source: https://www.sec.gov/Archives/edgar/data/2100782/000119312526085939/0001193125-26-085939-index.htm - Mar 2, 2026: Jason Silvers (President & CFO) bought 2,000 shares, about $32,000. Source: https://www.sec.gov/Archives/edgar/data/2100782/000119312526085898/0001193125-26-085898-index.htm - Mar 2, 2026: Noubar Afeyan (Director) bought 4,687,500 shares, about $75.0M. Source: https://www.sec.gov/Archives/edgar/data/2100782/000119312526085888/0001193125-26-085888-index.htm - Mar 2, 2026: Jane L. Mendillo (Director) bought 1,500 shares, about $24,000. Source: https://www.sec.gov/Archives/edgar/data/2100782/000119312526085872/0001193125-26-085872-index.htm - Mar 2, 2026: Noubar Afeyan (Director) bought 4,687,500 shares, about $75.0M. Source: https://www.sec.gov/Archives/edgar/data/2100782/000119312526085855/0001193125-26-085855-index.htm ## What management said - "Our team’s focus on execution for our clinical programs and translating our generative biology platform into the next generation of differentiated medicines drove strong progress in the second quarter" Mike Nally, chief executive officer of Generate Biomedicines Inc (8-K filed Aug 6, 2026). Source: https://www.sec.gov/Archives/edgar/data/2100782/000119312526336462/ck0002100782-ex99_1.htm - "Our platform and continued pipeline progress create optionality" Jason Silvers, president and chief financial officer of Generate Biomedicines Inc (8-K filed Aug 6, 2026). Source: https://www.sec.gov/Archives/edgar/data/2100782/000119312526336462/ck0002100782-ex99_1.htm ## Latest filings - 8-K filed Aug 26, 2026: https://www.sec.gov/Archives/edgar/data/2100782/000119312526365556/ck0002100782-20260825.htm - 10-Q filed Aug 6, 2026: https://www.sec.gov/Archives/edgar/data/2100782/000119312526336437/ck0002100782-20260630.htm ## About this data SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from. Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/